

Appl. No. 10/086,972  
Amdt. dated May 2, 2005  
Reply to Office action of February 2, 2005

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-3. (Canceled)

Claim 4. (Currently amended) The method of Claim ~~1~~ 21, wherein said animal exhibits signs or symptoms of ~~an inflammatory, infective, leukoproliferative, a neurodegenerative, or post-traumatic~~ condition.

Claim 5. (Currently amended) The method of Claim 4, wherein said sign or symptom is in ~~neural tissue; lymphoid tissue; myeloid tissue; pancreas; gastrointestinal tissue; thyroid tissue; muscle tissue; or skin or collagenous tissue.~~

Claims 6-9 (Canceled)

Claim 10. (Currently amended) The method of Claim ~~7~~ 21, wherein said ~~administering~~ contacting is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

Claims 11-17 (Canceled)

Claim 18. (Currently amended) The method of Claim ~~17~~ 22, wherein said ~~administering~~ contacting is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

Claims 19-20 (Canceled)

Appl. No. 10/086,972  
Amdt. dated May 2, 2005  
Reply to Office action of February 2, 2005

**Claim 21. (New)** A method of inhibiting activation of a microglial cell comprising contacting the microglial cell with mammalian OX2.

**Claim 22 (New)** A method of inhibiting activation of a microglial cell in neural tissue, comprising contacting the microglial cell in the tissue with mammalian OX2 protein.